logo
Plus   Neg
Share
Email

Teva Reports Positive Topline Phase IIIb Results With Fremanezumab - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from the Phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who suffer from either chronic or episodic migraine, patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days versus placebo over the 12 week assessment period, for both monthly and quarterly dosing regimens. The patients treated with fremanezumab experienced significant improvement compared to placebo on all secondary endpoints for both quarterly and monthly dosing regimens.

Teva plans to submit the full results for medical meetings in 2019, as well as peer-reviewed publication.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a batch of renewable energy deals totaling 1.6 GW through 18 acquisitions spread across three continents. The deals are intended to "spur the construction of more than $2 billion in new energy infrastructure," the company said. Google said the deals will increase its worldwide portfolio... Beyond Meat's main competitor Impossible Foods will launch its grocery store in California on Friday. Beyond Meat Inc. (BYND), the meatless burger and sausage maker, announced the appointment of Sanjay Shah as Chief Operating Officer. Shah will assume the responsibility for Beyond Meat's global operations and production, effective September 18.
Follow RTT
>